These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing, reported early||2004-000443-17||A Randomized, Double-Blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis||not-yet-due|
|Reported results||2004-003754-26||A Randomized Trial of Switching Antiviral Therapy from Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults with Chronic Hepatitis B||2006-12-05||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2004-004274-87||An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies||2010-05-27||bad-data|
|Exempt, with results||2008-005558-19||A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naïve Subjects Infected with Genotype 1 Chronic Hepatitis C||2010-01-10||not-yet-due|
|Exempt, with results||2009-018079-15||A Phase I/IIa Study Assessing Single and Multiple Doses of HCV Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects||2010-08-30||not-yet-due|
|Reported results||2011-001878-25||A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Genotype 1...||2014-10-31||due-trials|
|Reported results Terminated||2012-005636-29||3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting...||2015-03-20||due-trials|
|Exempt, with results||2013-004043-23||A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects||not-yet-due|